Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Enterprise Value (EV) 

Microsoft Excel

Current Enterprise Value (EV)

Edwards Lifesciences Corp., current enterprise value calculation

Microsoft Excel
Current share price (P) $107.73
No. shares of common stock outstanding 623,207,437
US$ in thousands
Common equity (market value)1 67,138,137
Add: Preferred stock, $.01 par value, no shares outstanding (per books)
Total equity 67,138,137
Add: Short-term debt (per books)
Add: Long-term debt (per books) 595,700
Total equity and debt 67,733,837
Less: Cash and cash equivalents 862,800
Less: Short-term investments 604,000
Enterprise value (EV) 66,267,037

Based on: 10-K (reporting date: 2021-12-31).

1 Common equity (market value) = Share price × No. shares of common stock outstanding
= 107.73 × 623,207,437



Historical Enterprise Value (EV)

Edwards Lifesciences Corp., EV calculation

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Share price1, 2 $107.73 $87.65 $76.85 $59.26 $44.61
No. shares of common stock outstanding1 623,207,437 624,518,873 627,367,734 623,298,987 630,071,124
US$ in thousands
Common equity (market value)3 67,138,137 54,739,079 48,213,210 36,936,698 28,107,473
Add: Preferred stock, $.01 par value, no shares outstanding (book value)
Total equity 67,138,137 54,739,079 48,213,210 36,936,698 28,107,473
Add: Short-term debt (book value) 598,000
Add: Long-term debt (book value) 595,700 595,000 594,400 593,800 438,400
Total equity and debt 67,733,837 55,334,079 48,807,610 37,530,498 29,143,873
Less: Cash and cash equivalents 862,800 1,183,200 1,179,100 714,100 818,300
Less: Short-term investments 604,000 219,400 337,800 242,400 519,200
Enterprise value (EV) 66,267,037 53,931,479 47,290,710 36,573,998 27,806,373

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 Closing price as at the filing date of Edwards Lifesciences Corp. Annual Report.

3 2021 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 107.73 × 623,207,437


The financial data from 2017 through 2021 displays a consistent upward trend in key equity and valuation metrics.

Common equity (market value) and total equity
Both items share identical values over the periods, indicating that total equity is fully represented by common equity market value. The figure grows steadily each year, starting from approximately 28.1 billion in 2017 and rising to around 67.1 billion by the end of 2021. This more than doubles the equity within five years, highlighting significant value growth attributable to potentially increased market capitalization or retained earnings.
Total equity and debt
Total equity and debt figures also follow an increasing trajectory, albeit at a somewhat slower rate than equity alone. The value rises from about 29.1 billion in 2017 to nearly 67.7 billion in 2021. This growth suggests incremental increases in leverage or debt alongside equity expansion, though the gap between total equity and total equity plus debt remains relatively narrow throughout the period, implying moderate debt levels relative to equity.
Enterprise value (EV)
Enterprise value, representing the total valuation of the company including debt, shows consistent growth in line with equity and total capitalization metrics. It increases from approximately 27.8 billion in 2017 to around 66.3 billion by 2021. The close relationship between EV and total equity and debt figures signifies a stable capital structure with market valuation closely aligned to book equity and debt values.

Overall, the data demonstrates sustained growth in the company’s value and capital base over the five-year period, with equity as the primary driver of expansion. Incremental debt usage appears measured, supporting the company's growth without significantly increasing leverage risk. The alignment between enterprise value and total equity plus debt further indicates market confidence reflecting book values comprehensively.

AI Ask an analyst for more